Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 637 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Healthy and Delicious Figs September 10, 2021 Breast Cancer Patient Takes Silly Pictures During Each Radiation Treatment to... March 25, 2021 Mohs Surgery for Skin Cancer: What to Know and What to... March 28, 2023 News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer... June 27, 2020 Load more HOT NEWS Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... Selumetinib Approved by FDA to Treat Children with NF1 FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction...
